Identification of polypharmacy patterns in new‐users of metformin using the Apriori algorithm: A novel framework for investigating concomitant drug utilization through association rule mining
Pharmacoepidemiology and Drug Safety · 2023
DOI: 10.1002/pds.5583 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmacoepidemiology and Drug Safety, 2023. Verfasst von Maria Luisa Faquetti und 4 weiteren Autor:innen. Beteiligte Einrichtung: ETH Zurich, Department of Chemistry and Applied Biosciences, Institute of Pharmaceutical Sciences, Zurich, Switzerland. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Metformin, Drug-Related Side Effects and Adverse Reactions. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Eidgenössische Technische Hochschule Zürich, ETH Zürich Foundation.
Themen: Medikationssicherheit
Abstract (Originalsprache)
Purpose
With increased concomitant chronic diseases in type 2 diabetes mellitus (T2DM), the use of multiple drugs increases as well as the risk of drug–drug interactions (DDI) and adverse drug reactions (ADR). Nevertheless, how medication patterns vary in T2DM patients across different sex and age groups is unclear. This study aims to identify and quantify common drug combinations in first‐time metformin users with polypharmacy (≥5 co‐medications).
Methods
New users of metformin were identified from the IQVIA Medical Research Data incorporating data from THIN, A Cegedim Database (2016–2019). A descriptive cohort study explored prescription patterns in patients with polypharmacy. The Apriori algorithm, used to find frequent item‐sets in databases, was first‐time applied to identify and quantify drug combinations of up to seven drugs to investigate potential harmful polypharmacy patterns.
Results
The cohort included 34 169 new‐users of metformin, of which 20 854 (61.0%) received polypharmacy. Atorvastatin was the most frequently co‐prescribed drug with metformin overall (38.7%), in women (34.3%) and men (42.6%). In the stratified analysis, a higher proportion of women received polypharmacy (65.6%) compared to men (57.4%). Moreover, the proportion of patients receiving polypharmacy increased with age (18–39 years = 30.4%, 40–59 years = 50.5%, 60–74 years = 70.9%, and ≥75 years = 84.3%).
Conclusion
This study is the first to identify and quantify commonly prescribed combinations of drugs compounds in patients with polypharmacy using the Apriori algorithm. The high polypharmacy prevalence at all strata indicates the need to optimize polypharmacy to minimize DDI and ADR.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- ETH Zurich, Department of Chemistry and Applied Biosciences, Institute of Pharmaceutical Sciences, Zurich, Switzerland.
- EPFL, Swiss Data Science Center (SDSC), Lausanne, Switzerland.
ORCID-Profile: Maria Luisa Faquetti, Adrian Martinez-De la Torre, Theresa Burkard, Guillaume Obozinski, Andrea M Burden
Förderung
- Eidgenössische Technische Hochschule Zürich
- ETH Zürich Foundation
Zitieren
APA
Faquetti, M. L., la Torre, A. M., Burkard, T., Obozinski, G., & Burden, A. M. (2023). Identification of polypharmacy patterns in new‐users of metformin using the Apriori algorithm: A novel framework for investigating concomitant drug utilization through association rule mining. Pharmacoepidemiology and Drug Safety. https://doi.org/10.1002/pds.5583
Vancouver
Faquetti ML, la Torre AM, Burkard T, Obozinski G, Burden AM. Identification of polypharmacy patterns in new‐users of metformin using the Apriori algorithm: A novel framework for investigating concomitant drug utilization through association rule mining. Pharmacoepidemiology and Drug Safety. 2023. doi:10.1002/pds.5583
BibTeX
@article{Faquetti2023,
author = {Faquetti, Maria Luisa and la Torre, Adrian Martinez-De and Burkard, Theresa and Obozinski, Guillaume and Burden, Andrea M},
title = {Identification of polypharmacy patterns in new‐users of metformin using the Apriori algorithm: A novel framework for investigating concomitant drug utilization through association rule mining},
journal = {Pharmacoepidemiology and Drug Safety},
year = {2023},
doi = {10.1002/pds.5583}
}
EUVIMED